AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12955866 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical training and lifestyle education (LSE)
Number of subjects: 55
Study 12955866 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity physical training and lifestyle education (LSE)
Number of subjects: 55
Study 12955866 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle education only (LSE)
Number of subjects: 55
Study 11764135 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-oxygen (HeO2) breathing for a 12-hour period
Number of subjects: 16
Study 11764135 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (conventional treatment)
Number of subjects: 16
Study 1672049 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 1 mg/kg and fentanyl 2 micrograms/kg
Number of subjects: 44
Study 1672049 — intervention group
Group type: COMPARATOR
Intervention: placebo (normal saline)
Number of subjects: 44
Study 1672049 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol 1 mg/kg
Number of subjects: 44
Study 1672049 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl 3.5 micrograms/kg
Number of subjects: 44
Study 6134622 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxmetidine (100 mg)
Number of subjects: 11
Study 6134622 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxmetidine (200 mg)
Number of subjects: 11
Study 30676284 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Fluoroamphetamine (4-FA)
Number of subjects: 12
Study 30676284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29474792 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic-only movement breaks
Number of subjects: 460
Study 29474792 — intervention group
Group type: COMPARATOR
Intervention: Academic-based breaks
Number of subjects: 460
Study 27598693 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 27598693 — intervention group
Group type: COMPARATOR
Intervention: Short-term Psychodynamic Supportive Psychotherapy (SPSP)
Number of subjects: 0
Study 24588905 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) 5 mg, single intravenous infusion
Number of subjects: 40
Study 24588905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22349209 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-taurine energy drink (AdvoCare Spark)
Number of subjects: 20
Study 22349209 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic, isovolumetric, non-caffeinated placebo
Number of subjects: 20
Study 20213586 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynostemma pentaphyllum tea (6 g daily for 12 weeks)
Number of subjects: 24
Study 20213586 — intervention group
Group type: COMPARATOR
Intervention: Placebo tea
Number of subjects: 24
Study 16573847 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg/d, increased by 50 mg weekly to a maximum of 150 or 300 mg/d)
Number of subjects: 265
Study 16573847 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 265
Study 16573847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 16342349 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (12 microg/kg loading dose for 15 minutes)
Number of subjects: 24
Study 16342349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12105237 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate binders (including sevelamer hydrochloride, magnesium-based, iron-based, and lanthanum-based compounds)
Number of subjects: 0
Study 12105237 — intervention group
Group type: COMPARATOR
Intervention: Aluminium gels and calcium salts (historical context)
Number of subjects: 0
Study 9790388 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 204
Study 9790388 — intervention group
Group type: COMPARATOR
Intervention: Bladder training
Number of subjects: 204
Study 9790388 — intervention group
Group type: COMPARATOR
Intervention: Pelvic muscle exercise with biofeedback‐assisted instruction
Number of subjects: 204
Study 8540504 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered expandable metal stents
Number of subjects: 6
Study 2022199 — intervention group
Group type: EXPERIMENTAL
Intervention: Power athletes
Number of subjects: 13
Study 2022199 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance athletes
Number of subjects: 13
Study 2022199 — intervention group
Group type: EXPERIMENTAL
Intervention: Both power and endurance athletes
Number of subjects: 13
Study 7011819 — intervention group
Group type: EXPERIMENTAL
Intervention: SB 7505 100 mg/day
Number of subjects: 20
Study 7011819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31686796 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyadic strength-based empowerment program (D‐StEP‐MCI, n=52)
Number of subjects: 103
Study 31686796 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=51)
Number of subjects: 103
Study 28346969 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic varicocoelectomy
Number of subjects: 84
Study 28346969 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical varicocoelectomy
Number of subjects: 84
Study 27031322 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 cc dextrose 5% (group A)
Number of subjects: 50
Study 27031322 — intervention group
Group type: COMPARATOR
Intervention: 500 cc normal saline (group B)
Number of subjects: 50
Study 24210727 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise program
Number of subjects: 40
Study 24210727 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 40
Study 21925828 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 0
Study 21925828 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0
Study 21925828 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined behavioral intervention
Number of subjects: 0
Study 21925828 — intervention group
Group type: EXPERIMENTAL
Intervention: T5: daily heavy drinkers stopping early
Number of subjects: 0
Study 21925828 — intervention group
Group type: EXPERIMENTAL
Intervention: T1: frequent heavy drinkers
Number of subjects: 0
Study 21925828 — intervention group
Group type: EXPERIMENTAL
Intervention: T2: very frequent heavy drinkers
Number of subjects: 0
Study 21925828 — intervention group
Group type: EXPERIMENTAL
Intervention: T3: nearly daily heavy drinkers
Number of subjects: 0
Study 21925828 — intervention group
Group type: EXPERIMENTAL
Intervention: T4: daily heavy drinkers
Number of subjects: 0
Study 19414713 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with sertraline hydrochloride
Number of subjects: 174
Study 19414713 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term treatment with sertraline hydrochloride
Number of subjects: 174
Study 19414713 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe symptoms at baseline
Number of subjects: 174
Study 19414713 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission with treatment
Number of subjects: 174
Study 19414713 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 174
Study 17786691 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% maltodextrin, 3% lemon juice solution (carbohydrate trial)
Number of subjects: 7
Study 17786691 — intervention group
Group type: COMPARATOR
Intervention: 3% lemon juice placebo mouthwash (placebo trial)
Number of subjects: 7
Study 17786691 — intervention group
Group type: EXPERIMENTAL
Intervention: Both trials
Number of subjects: 7
Study 15117902 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg bid for at least 16 weeks)
Number of subjects: 73
Study 15117902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 15117902 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 73
Study 12081984 — intervention group
Group type: EXPERIMENTAL
Intervention: LL genotype of the SLC6A4 polymorphism
Number of subjects: 1359
Study 12081984 — intervention group
Group type: EXPERIMENTAL
Intervention: S allele frequency
Number of subjects: 1359
Study 12081984 — intervention group
Group type: COMPARATOR
Intervention: Genotype percentages
Number of subjects: 1359
Study 9661120 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral liquid supplement containing arginine
Number of subjects: 0
Study 9661120 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral liquid supplement containing arginine plus omega-3 fatty acids
Number of subjects: 0
Study 9661120 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplement)
Number of subjects: 0
Study 7862598 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling from qualified counselors in primary health care
Number of subjects: 0
Study 7862598 — intervention group
Group type: COMPARATOR
Intervention: Usual advice from general practitioners
Number of subjects: 0
Study 7862598 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling from qualified counselors
Number of subjects: 0
Study 2246697 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (10 mg/kg)
Number of subjects: 110
Study 2246697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 7437245 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate (single dose)
Number of subjects: 24
Study 7437245 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin lactobionate (four doses)
Number of subjects: 24
Study 7437245 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive sampling of urine and saliva
Number of subjects: 24
Study 31332901 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled allergens
Number of subjects: 309
Study 31332901 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingested allergens
Number of subjects: 309
Study 31332901 — intervention group
Group type: EXPERIMENTAL
Intervention: Children (1-13 years old)
Number of subjects: 309
Study 31332901 — intervention group
Group type: EXPERIMENTAL
Intervention: Teenagers (14-18 years old)
Number of subjects: 309
Study 31332901 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults (above 18 years old)
Number of subjects: 309
Study 29939045 — intervention group
Group type: EXPERIMENTAL
Intervention: Leader-focused mental health training
Number of subjects: 82
Study 28319552 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of 0.5% mepivacaine (LC group)
Number of subjects: 50
Study 28319552 — intervention group
Group type: COMPARATOR
Intervention: 5 mL of 1% mepivacaine (HC group)
Number of subjects: 50
Study 25890186 — intervention group
Group type: EXPERIMENTAL
Intervention: PALM/LHW intervention
Number of subjects: 178
Study 25890186 — intervention group
Group type: EXPERIMENTAL
Intervention: PALMPLUS intervention
Number of subjects: 178
Study 25890186 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 178
Study 23683859 — intervention group
Group type: EXPERIMENTAL
Intervention: 2g/kg IVIg body weight infused over 5 consecutive days
Number of subjects: 51
Study 23683859 — intervention group
Group type: COMPARATOR
Intervention: Placebo infused over 5 consecutive days
Number of subjects: 51
Study 22095836 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin, mineral, and herbal supplement for 8 weeks
Number of subjects: 50
Study 22095836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19266367 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg PO bid continuously until disease progression
Number of subjects: 24
Study 19266367 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and etoposide (EP) up to 6 cycles
Number of subjects: 24
Study 19266367 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 24
Study 17253179 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue microarray
Number of subjects: 37
Study 17253179 — intervention group
Group type: COMPARATOR
Intervention: Routine immunohistochemistry (IHC)
Number of subjects: 37
Study 17253179 — intervention group
Group type: EXPERIMENTAL
Intervention: hMSH2 expression
Number of subjects: 37
Study 17253179 — intervention group
Group type: EXPERIMENTAL
Intervention: hMLH1 expression
Number of subjects: 37
Study 15041875 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (0.8 to 1.2 mg/kg for 3 days)
Number of subjects: 289
Study 15041875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 11483325 — intervention group
Group type: EXPERIMENTAL
Intervention: HF‐ACC‐RCT with 2 cycles of 5‐FU (600 mg/m(2)/day)/carboplatinum (70 mg/m(2)) on days 1‐5 and 29‐33
Number of subjects: 263
Study 11483325 — intervention group
Group type: COMPARATOR
Intervention: HF‐ACC‐RT alone
Number of subjects: 263
Study 11483325 — intervention group
Group type: EXPERIMENTAL
Intervention: HF‐ACC‐RCT
Number of subjects: 263
Study 11483325 — intervention group
Group type: COMPARATOR
Intervention: HF‐ACC‐RT
Number of subjects: 263
Study 11483325 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactically given G‐CSF (263 microg, days 15‐19)
Number of subjects: 263
Study 9740569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices (n=13) using a nurse facilitator to improve screening for haemoglobin disorders
Number of subjects: 26
Study 9740569 — intervention group
Group type: COMPARATOR
Intervention: Control practices (n=13)
Number of subjects: 26
Study 9740569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices (n=13) adjusted for baseline requests
Number of subjects: 26
Study 8056991 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 15
Study 8056991 — intervention group
Group type: COMPARATOR
Intervention: Clemastine 2 mg (positive control)
Number of subjects: 15
Study 2569997 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg
Number of subjects: 20
Study 2569997 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine 4 mg
Number of subjects: 20
Study 2569997 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine 1 mg
Number of subjects: 20
Study 2569997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 782307 — intervention group
Group type: EXPERIMENTAL
Intervention: C-1 group: 32 patients received one dose of i.t. methotrexate at the end of induction treatment and every three months.
Number of subjects: 61
Study 782307 — intervention group
Group type: COMPARATOR
Intervention: C-2 group: 29 patients treated by cranial irradiation (2400 r.) and five doses of i.t. methotrexate after induction of remission.
Number of subjects: 61
Study 31893730 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual-acoustic biofeedback
Number of subjects: 60
Study 31893730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound biofeedback
Number of subjects: 60
Study 28462585 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 0
Study 28462585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26376136 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered sunlight
Number of subjects: 447
Study 26376136 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 447
Study 23565941 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 65
Study 23565941 — intervention group
Group type: COMPARATOR
Intervention: No Fresh Frozen Plasma (no FFP)
Number of subjects: 65
Study 21359424 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type-A (BoNT/A) administered as a 40 μl bolus, lateral to their nose, at 24 hours, 8, 15, 22, 29 or 36 days pre-formalin test (FT)
Number of subjects: 0
Study 21359424 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution 0.9% (control)
Number of subjects: 0
Study 19343373 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of paracetamol
Number of subjects: 43
Study 19343373 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 43
Study 16772783 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (0.05 mg/kg body weight)
Number of subjects: 44
Study 14706580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine hydrochloride 1,200 mg daily (H(2)-blocker)
Number of subjects: 80
Study 14706580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine hydrochloride 200 mg daily (H(2)-blocker)
Number of subjects: 80
Study 14706580 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg twice daily for 5 days
Number of subjects: 80
Study 14706580 — intervention group
Group type: COMPARATOR
Intervention: Neither H(2)-blocker nor omeprazole
Number of subjects: 80
Study 11720833 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐selectin, ICAM‐1, VCAM‐1 serum levels in colorectal cancer patients
Number of subjects: 63
Study 11720833 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐selectin, ICAM‐1, VCAM‐1 serum levels post-surgery
Number of subjects: 63
Study 11720833 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative E‐selectin, ICAM‐1, VCAM‐1 levels
Number of subjects: 63
Study 11720833 — intervention group
Group type: COMPARATOR
Intervention: E‐selectin, ICAM‐1, VCAM‐1 levels
Number of subjects: 63
Study 9159837 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable CAPD patients (n = 11)
Number of subjects: 16
Study 9159837 — intervention group
Group type: COMPARATOR
Intervention: Bacterial peritonitis patients (n = 5)
Number of subjects: 16
Study 7957835 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled bradykinin
Number of subjects: 9
Study 7957835 — intervention group
Group type: COMPARATOR
Intervention: Placebo (methacholine)
Number of subjects: 9
Study 3546716 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (1.5 g daily for 10 days)
Number of subjects: 133
Study 3546716 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (1.5 g daily for 10 days)
Number of subjects: 133
Study 3546716 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole (1 g daily for 10 days)
Number of subjects: 133
Study 3546716 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (0.5 g daily for 10 days)
Number of subjects: 133
Study 3546716 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (single 2 g dose)
Number of subjects: 133
Study 3546716 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornidazole (single 1 g dose)
Number of subjects: 133
Study 29428546 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendation menu (vegetarian dish presented as chef's recommendation)
Number of subjects: 0
Study 29428546 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive menu (more appealing description of vegetarian dish)
Number of subjects: 0
Study 29428546 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian menu (vegetarian dishes placed in a separate section)
Number of subjects: 0
Study 29428546 — intervention group
Group type: COMPARATOR
Intervention: Control menu (all dishes presented in the same manner)
Number of subjects: 0
Study 27579357 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based Instruction (VI)
Number of subjects: 50
Study 27579357 — intervention group
Group type: COMPARATOR
Intervention: Conventional Instruction (CI)
Number of subjects: 50
Study 24553359 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference-education intervention
Number of subjects: 168
Study 24553359 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 168
Study 23521140 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine 40 mg (20 mg/ml)
Number of subjects: 34
Study 23521140 — intervention group
Group type: COMPARATOR
Intervention: Chloroprocaine 40 mg (20 mg/ml)
Number of subjects: 34
Study 20662773 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 47
Study 20662773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 18294804 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking Safety
Number of subjects: 353
Study 18294804 — intervention group
Group type: COMPARATOR
Intervention: Women's Health Education
Number of subjects: 353
Study 17119689 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (10 mg/kg)
Number of subjects: 75
Study 17119689 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dipyrone (15 mg/kg)
Number of subjects: 75
Study 17119689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular dipyrone (15 mg/kg)
Number of subjects: 75
Study 17119689 — intervention group
Group type: COMPARATOR
Intervention: All groups (oral ibuprofen, oral dipyrone, intramuscular dipyrone)
Number of subjects: 75
Study 17119689 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dipyrone
Number of subjects: 75
Study 17119689 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 75
Study 12734758 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged intermittent high-intensity single-leg pedalling exercise task (PIHIET)
Number of subjects: 13
Study 11026949 — intervention group
Group type: EXPERIMENTAL
Intervention: New forms of psychological treatment for women newly diagnosed with early-stage breast cancer
Number of subjects: 0
Study 11026949 — intervention group
Group type: EXPERIMENTAL
Intervention: New forms of psychological treatment for families at risk of maladaptive bereavement
Number of subjects: 0
Study 8792361 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg, 1 capsule/day for 14 days)
Number of subjects: 8
Study 8792361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1284159 — intervention group
Group type: EXPERIMENTAL
Intervention: IS‐5‐MN 20 mg three times daily
Number of subjects: 15
Study 1284159 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil 50 mg three times daily
Number of subjects: 15
Study 1284159 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IS‐5‐MN and gallopamil (same dosages as above)
Number of subjects: 15
Study 1284159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3969934 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight lifting exercise with RDA protein intake (0.8 g/(kg BW X d))
Number of subjects: 13
Study 3969934 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight lifting exercise with 3 X RDA protein intake
Number of subjects: 13
Study 3969934 — intervention group
Group type: COMPARATOR
Intervention: No exercise with RDA protein intake
Number of subjects: 13